Noramco and Willow Biosciences to jointly develop a biosynthesis platform for synthetic CBD

New activity will add options and cost savings to Noramco’s robust CBD platform

Related Articles

FormattedPicture

NUTRITION & HEALTH NEWS

19 Jun 2019 --- Set to be launched in September, the International Cannabinoid Analysis Program (ICAP) is a new third-party certification program for manufacturers and brands in... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

05 Jun 2019 --- US-based hemp ingredients company Victory Hemp Foods has launched two new functional and proprietary ingredients – Victory ONE Hemp Heart Oil and V-70 Hemp... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

31 May 2019 --- A synthetic, non-intoxicating cannabidiol (CBD) alternative, 8,9-Dihydrocannabidiol (H2CBD) was found to be as effective in treating the frequency and severity of... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

27 May 2019 --- Consumer interest in cannabidiol (CBD) is booming, with CBD-infused products proliferating at an astounding pace. Whether the cannabis extract has indeed proven its... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

27 May 2019 --- Regulatory confusion over cannabinoids (CBD) has opened up the space for alternatives, within which Gencor has released Levagen, a palmitoylethanolamide (PEA)... Read More